Eye drops containing a derivative of turmeric reduce the loss of retinal cells in rats, finds a new study led by UCL and Imperial College London researchers.
Loss of these cells is known to be an early sign of glaucoma and the eye drops could in time be a new treatment option for the condition.
In the new Scientific Reports paper, the researchers report a new method to deliver curcumin, extracted from the yellow spice turmeric, directly to the back of the eye using eye drops, overcoming the challenge of curcumin’s poor solubility.
They are also investigating how the eye drops could be used as a diagnostic tool for a range of conditions.
“Curcumin is an exciting compound that has shown promise at detecting and treating the neurodegeneration implicated in numerous eye and brain conditions from glaucoma to Alzheimer’s disease, so being able to administer it easily in eye drops may end up helping millions of people,” said the study’s lead author, Professor Francesca Cordeiro (UCL Institute of Ophthalmology, Western Eye Hospital and Imperial College London).
Glaucoma is a group of eye conditions affecting over 60 million people worldwide that leads to irreversible blindness in 1 in 10 cases. The condition mainly involves the loss of retinal ganglion cells, a type of neuron located near the surface of the retina. Stopping the loss of these cells early on has not yet been achieved, so it is a key focus of glaucoma research.
Curcumin has previously been shown to protect retinal ganglion cells when administered orally. For the current study, the researchers were seeking to find a more reliable method to deliver curcumin. Oral administration is difficult because curcumin has poor solubility, so it does not easily dissolve and get absorbed into the bloodstream, and would require people to take large amounts of tablets (up to 24 a day) that may cause gastrointestinal side effects.
The team developed a novel nanocarrier, wherein the curcumin is contained within a surfactant combined with a stabiliser, both of which are known to be safe for human use and are already in existing eye products. The nanocarrier can be used in eye drops to deliver much higher loads of curcumin than other products in development, increasing the drug’s solubility by a factor of almost 400,000, and localises the curcumin in the eyes instead of throughout the body.
The researchers initially tested the product on cells that are used to model glaucoma, before conducting trials in rats with eye conditions involving the loss of retinal ganglion cells.
After twice-daily use of eye drops in the rats for three weeks, retinal ganglion cell loss was significantly reduced compared to matched controls, and the treatment was found to be well-tolerated with no signs of eye irritation or inflammation.
Having found an effective way to deliver curcumin, the researchers are hopeful that it could also be used to diagnose Alzheimer’s disease, as curcumin is known to bind to the amyloid beta protein deposits implicated in Alzheimer’s, and can be detected in the retina with fluorescence to highlight the malignant proteins.
“We are now researching diagnostic uses for these eye drops alongside other ways to visualise the retina, as eye tests can be an opportunity to detect signs of neurodegeneration with a simple, non-invasive test,” said co-lead author Dr Ben Davis (UCL Institute of Ophthalmology and Imperial College London).
Professor Cordeiro added: “As we live longer, diseases such as glaucoma and Alzheimer’s are steadily increasing. We believe our findings could make a major contribution at helping the lives of people affected by these devastating diseases.”
The Latest on: Glaucoma
via Google News
The Latest on: Glaucoma
- Indian, US scientists to begin collaborative research to tackle diabetic retinopathy, glaucoma with govt funding on September 18, 2018 at 7:30 pm
Indian academia and non-profit institutions conducting research on blinding eye diseases such as diabetic retinopathy, glaucoma and age-related macular degeneration (AMD) that affect millions of peopl... […]
- Secondary Ocular Hypertension and the Risk of Glaucoma Surgery After Dexamethasone Intravitreal Implant in Routine Clinical Practice on September 18, 2018 at 1:36 pm
To determine the rate of ocular hypertension (OHT) after dexamethasone intravitreal implant in routine clinical practice and identify patient characteristics associated with a risk for glaucoma surger... […]
- Glaucoma & Pot: The truth behind the myths on September 18, 2018 at 12:04 pm
(NBC News) Google “marijuana glaucoma” and you’ll find gobs of information claiming cannabis treats the eye condition. But what’s real, and what’s not? Glaucoma expert Dr. Dana ... […]
- Hairy Biker 'shocked' to discover during a routine eye examination he had glaucoma on September 18, 2018 at 4:10 am
The record number of older people in employment are being urged to make their eye health a priority as pension entitlement ages increase. Official figures show that there are now more than 1.2 million ... […]
- Glaucoma Treatment Market: By Production, Revenue, Share, Price, Gross Margin Analysis and forecasts on September 17, 2018 at 8:11 pm
This Report would help Business Leader, Market Intelligence, Marketing Head & CEO's, Marketing and strategy head, Managing Consultanting firms etc. in understanding Glaucoma Treatment market size, CAG... […]
- The global glaucoma market explored in latest research on September 17, 2018 at 4:12 am
Global glaucoma Market major player include: Novartis AG,Allergan Inc.,Merck & Co.,Akron, Inc. Glaucoma is the second most common leading cause of blindness and is commonly observed in the older popul... […]
- Hairy Bikers’ Dave Myers reveals he nearly went blind after mistaking glaucoma for a hangover on September 15, 2018 at 4:57 pm
The 61-year-old feared the condition could put an end to his TV career and passion for bikes The chef, 61, was having a check-up at the opticians when he was told he had signs of the serious eye-condi... […]
- Abuja Civil servant Reveals Herbal Remedy That Treats Glaucoma, Cataract and Restores Eyesight in Few Weeks! on September 15, 2018 at 6:00 am
If you’re tired of struggling with poor eyesight, specifically someone who wants to improve their vision, reverse glaucoma, cataract, near-sightedness and wants to stop using glasses, then here is goo... […]
- FDA OKs Sun Pharma's Xelpros for lowering IOP in glaucoma patients on September 14, 2018 at 8:21 am
The FDA approves Sun Pharmaceuticals' (OTCPK:SMPQY) XELPROS (latanoprost ophthalmic emulsion) 0.005% for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular ... […]
via Bing News